MedTrace Logo

Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

NCT00676845 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 133

Last updated 2018-12-24

No results posted yet for this study

Summary

This study will analyse the dose-dependent effect of olmesartan medoxomil on the change in arterial stiffness in subjects with hypertension and metabolic syndrome

Conditions

Interventions

DRUG

olmesartan medoxomil

dosage form: oral tablet; frequency: daily; duration: 52 weeks

DRUG

placebo

dosage form: tablet; frequency: daily; duration: 3 weeks

DRUG

olmesartan medoxomil

dosage form: oral tablet; frequency: daily; duration: 52 weeks

DRUG

olmesartan medoxomil

dosage form: oral tablet; frequency: daily; duration: 52 weeks

Sponsors & Collaborators

  • Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • Belgium
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676845 on ClinicalTrials.gov